We are a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. Our lead drug candidate is Pracinostat, a potential best-in-class, oral HDAC inhibitor currently in development for MDS and AML. We are also developing ME-344, a novel mitochondrial inhibitor, and PWT143, a highly selective PI3K delta inhibitor.
[ Read more ]
MEI Pharma to Present at Cowen Health Care Conference [ Webcast ]
MEI Pharma Reaches Response Milestone in Phase II Clinical Trial of Pracinostat in Refractory MDS
[ December 22, 2014 ]
MEI Pharma Completes Public Offering of Common Stock
[ December 17, 2014 ]
Click here for our 2014 Annual Review